OmniAb raises 2026 revenue and cash guidance on partner pipeline momentum
Several OmniAb-derived antibody programs advanced in the quarter, including a Phase 3 start for Johnson & Johnson's ramantamig and new Phase 2b plans for Teva's TEV-'408 in vitiligo.
SEC filing